Skip to content
Yervoy(ipilimumab)
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Drugs Approved for Childhood Cancers
BMS
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
Yervoy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ipilimumab
Tradename
Proper name
Company
Number
Date
Products
YervoyipilimumabBristol-Myers Squibb CompanyN-125377 RX2011-03-25
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
yervoyBiologic Licensing Application2020-11-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
melanomaD008545
Agency Specific
FDA
EMA
Expiration
Code
ipilimumab, Yervoy, Bristol-Myers Squibb Company
2027-10-02Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
L01FX04: Ipilimumab
HCPCS
Code
Description
J9228
Injection, ipilimumab, 1 mg
Clinical
Clinical Trials
705 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD0085459913116213223
Renal cell carcinomaD00229217256145
Lung neoplasmsD008175C34.9071141121
Kidney neoplasmsD007680EFO_0003865C6425119
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8052563185
Non-small-cell lung carcinomaD00228929401266
Prostatic neoplasmsD011471C611222234
Colorectal neoplasmsD0151791215224
GlioblastomaD005909EFO_0000515762115
Liver neoplasmsD008113EFO_1001513C22.098215
SarcomaD01250979114
Small cell lung carcinomaD05575268112
Stomach neoplasmsD013274EFO_0003897C163629
Brain neoplasmsD001932EFO_0003833C7117119
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25161426
Uveal neoplasmsD014604EFO_1001230131423
Breast neoplasmsD001943EFO_0003869C501011120
Squamous cell carcinoma of head and neckD0000771958916
Non-hodgkin lymphomaD008228C85.99712
Myelodysplastic syndromesD009190D469211
Myeloid leukemia acuteD015470C92.010111
Ovarian neoplasmsD010051EFO_0003893C567811
Multiple myelomaD009101C90.07510
Urologic neoplasmsD014571C64-C688510
Show 125 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034044
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.233
Hematologic neoplasmsD01933722
Primary myelofibrosisD055728D47.422
Ovarian epithelial carcinomaD00007721622
AnemiaD000740EFO_0004272D64.911
Myeloid leukemia chronic-phaseD01546611
ThrombocytosisD013922D75.8311
Small cell carcinomaD01828811
Mycosis fungoidesD009182C84.011
Show 15 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIPILIMUMAB
INNipilimumab
Description
Ipilimumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)IPILIMUMAB
Structure (InChI/SMILES or Protein Sequence)
>7SU0:H,I|Fab heavy chain (PCA)VQLVESGGGVVQPGRSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVTFISYDGHNKYYADSVKGRFTISRDNSK NTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCGGHHHHHH >7SU0:L,M|Fab light chain EIVLTQSPGTLSLSPGERATLSCRASQEVGESELAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5TRU, 5XJ3, 6JC2, 6RP8, 7SU0, 7SU1
CAS-ID477202-00-9
RxCUI1094833
ChEMBL IDCHEMBL1789844
ChEBI ID
PubChem CID
DrugBankDB06186
UNII ID6T8C155666 (ChemIDplus, GSRS)
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Yervoy - Bristol Myers Squibb
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 35,612 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
199,331 adverse events reported
View more details